<*dv_1*>Asilas Genomic Systems (AGS) is a functional genomics company providing transgenic mouse models for human pathologies.  Transgenic mouse technology, pioneered by Professor Frank Ruddle at Yale University in the early 1980s, has led to the generation of mice carrying genes associated with human conditions.  These animal models provide evidence for the molecular basis of many diseases and serve as living substrates for assaying potential therapeutics.  With the demand for functional analysis at the level of the whole organism growing exponentially, developing new and more robust transgenic tools for rapid analysis is fundamentally important to the biopharmaceutical industry.

AGS goes beyond genomics to provide new insights into the molecular mechanisms of health and disease.  AGS has been able to leverage its patented techniques across a portfolio of applications in contracting transgenic services and creating disease model libraries, as well as providing a therapeutic drug discovery platform.  The centerpiece of the AGS technology is the recombinogenic targeting methodology based on a yeast-bacteria shuttle vector, pClasper.  This unique and powerful technology allows rapid modification of large genomic regions for transgenic analysis.  AGS performs disease-specific research and development both independently and in partnership with pharmaceutical companies and leading academic institutions.  Based on these technologies, AGS aims to become the leading supplier of transgenic animal disease models and partner in the study of complex disease pathologies.